Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

UPGRADE

Financiado

Unlocking cognition by Pulsatile GnRH in Alzheimer's DiseasE

Cognitive decline associated with Alzheimer disease (AD) and other age-related dementias affects ~55 million people worldwide, and is a growing problem in aging European societies. However, most drugs fail at clinical trial, and a... ver más

31/03/2025

INSERM

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-07-04

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

INSERM

150.00K€ | Lider

Proyectos interesantes

PID2019-107286RB-I00 PAPEL DEL ANTAGONISTA DE RECEPTORES DE MUERTE, FAIM-L EN LA... 167K€ Cerrado

BES-2010-040343 MEMORIA SEMANTICA: EVIDENCIA DE LA DEMENCIA FRONTO TEMPORAL... 43K€ Cerrado

PID2020-113878RB-I00 EFECTO DEL ENVEJECIMIENTO Y LA NEURODEGENERACION EN EL COMPO... 242K€ Cerrado

CNS2023-143768 Enfermedades del sistema nervioso 200K€ Cerrado

BES-2015-071253 DETERIORO COGNITIVO EN EL ENVEJECIMIENTO NORMAL, DCL Y EA: E... 93K€ Cerrado

RTC-2017-6424-1 Nuevos alimentos para prevención de enfermedades con deterio... 374K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 20 meses Fecha Inicio: 2023-07-04
Fecha Fin: 2025-03-31

Presupuesto del proyecto 150K€

Descripción del proyecto Cognitive decline associated with Alzheimer disease (AD) and other age-related dementias affects ~55 million people worldwide, and is a growing problem in aging European societies. However, most drugs fail at clinical trial, and approved treatments aimed at controlling or reversing pathological changes in the brain do not improve cognition in patients, besides having significant side effects. It is thus essential to design and test alternative approaches to enhance cognitive performance and reduce the personal, familial and societal burden of AD. There is abundant circumstantial evidence pointing to a correlation between cognitive decline or AD progression with the age-dependent loss or deregulation of gonadotropin-releasing hormone (GnRH), a neuropeptide better known for its role in the reproductive axis. Nevertheless, a link between the two processes has not been seriously considered. In a recent groundbreaking study, we have shown that AD-like cognitive deficits in Down syndrome stem from progressive GnRH loss, and restoring native GnRH in a physiologically relevant pulsatile pattern using implantable pumps safely and effectively improves cognition long after the onset of symptoms, together with augmented brain connectivity. Additionally, we have shown that tanycytes, specialized hypothalamic glial cells that control GnRH secretion, are fragmented in AD patient brains. Putting these two findings together, we hypothesize that cognitive performance in AD patients can also be enhanced by administering pulsatile GnRH at normally occurring doses, improving their quality of life,. The UPGRADE project will extend promising results we have obtained on the effectiveness of this strategy in a preclinical mouse model of AD, analyze GnRH activity and pulsatility in an existing cohort of AD patients, and finally, draft a clinical trial protocol to test the safety and efficacy of pulsatile GnRH therapy to reactivate cognitive reserves in patients with mild/moderate AD.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores